Disc Medicine : Corporate Presentation (May 2025)

Published: 2025-05-09 15:51:11 ET IRON

Published on 05/09/2025 at 15:51

May 2025

Bitopertin, DISC-0974, and DISC-3405 are investigational agents and are not approved for use as therapies in any jurisdiction worldwide

Iron

Iron and heme metabolism are critical pathways in hematology with genetically-validated targets

Key points of intervention across a wide range of diseases

Heme

Spectrum of Hematologic Diseases Addressable by Disc Portfolio

Severe Rare (000s)

Moderate Prevalence (100K+)

Widely Prevalent (MMs)

Diamond-Blackfan

Erythropoietic

Beta-

Anemia of

Myelodysplastic

Sickle Cell

Polycythemia

Hereditary

IBD

CKD

Anemia

Porphyrias

Thalassemia

Myelofibrosis

Syndromes

Disease

Vera

Hemochromatosis

Anemia

Anemia

Increase Iron Hepcidin Suppression

DISC-0974

(Anti-HJV mAb)

Phase 1b/2

Initial POC

Anemia of chronic diseases

Restrict Iron Hepcidin Induction

DISC-3405

(Anti-TMPRSS6 mAb)

Phase 1 Complete

Initial POM

Polycythemia vera and iron overload diseases

Modulate Heme

Synthesis

Bitopertin

(GlyT1 Inhibition)

Phase 2 Complete

Confirmatory trial initiated

Rare blood disorders

Disclaimer

Disc Medicine Inc. i published this content on May 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 09, 2025 at 19:50 UTC.